SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Amendment No. 1)
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction
|(Address of principal executive offices, including Zip Code)||(Registrant’s telephone number, including area code)|
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|Item 2.02.|| |
Results of Operations and Financial Condition.
On May 12, 2023, AVITA Medical, Inc. (the “Company”) furnished a Current Report on Form 8-K (the “Original Form 8-K”) with a transcript of the Company’s May 11, 2023 conference call discussing the Company’s financial results for its fiscal quarter ended March 31, 2023 as Exhibit 99.2. Exhibit 99.2 to the Original Form 8-K inadvertently included extraneous tabular information from S&P Global Market Intelligence, including financial results and consensus data for the quarter ended March 31, 2023 in Australian Dollars. The Company’s actual results are reported in U.S. Dollars and included $10.6 million in revenue and a net loss of $9.2 million, or $0.37 per share. For further details, please refer to the Company’s Form 10-Q filed with the SEC on May 11, 2023.
The information in Item 2.02 of this Current Report on Form 8-K/A is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 15, 2023
|AVITA MEDICAL, INC.|
/s/ Donna Shiroma